What if cancer cells could be re-engineered to turn against their own kind?
A new study in Science Translational Medicine, led by researchers at Brigham and Women’s Hospital, leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer. The team reports promising results in preclinical models across multiple types of cancer cells, establishing a potential roadmap toward clinical translation for treating primary, recurrent and metastatic cancer.
“This is just the tip of the iceberg,” said corresponding author Khalid Shah MS, PhD, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). “Cell-based therapies hold tremendous promise for delivering therapeutic agents to tumors and may provide treatment options where standard therapy has failed. With our technique, we show it is possible to reverse-engineer a patient’s own cancer cells and use them to treat cancer. We think this has many implications and could be applicable across all cancer cell types.”
The new approach capitalizes on cancer cells’ self-homing ability – the process in which cancer cells can track the cells of their kind that have spread within the same organ or to other parts of the body. Harnessing this power could overcome drug delivery challenges, helping get therapeutics to tumor sites that may otherwise be difficult to reach.
The team developed and tested two techniques to harness the power of cancer cells. The “off the shelf” technique used pre-engineered tumor cells that would need to be matched to a patient’s HLA phenotype (essentially, a person’s immune fingerprint). The “autologous” approach used CRISPR technology to edit the genome of a patient’s cancer cells and insert therapeutic molecules. These cells could then be transferred back into the patient.
To test both approaches, the team used mouse models of primary and recurrent brain cancer and breast cancer that has spread to the brain. The team saw direct migration of engineered cells to the sites of tumors and found evidence that the engineered cells specifically targeted and killed recurrent and metastatic cancer in the mice. The researchers report that the treatment increased the survival of the mice. Engineered cells were equipped with a “kill switch” that could be activated after treatment – PET imaging showed that this kill switch worked to eliminate the cells.
“Our study demonstrates the therapeutic potential of using engineered tumor cells and their self-homing properties for developing receptor-targeted therapeutics for various cancers,” said Shah.
Receive an email update when we add a new GENE EDITING article.
The Latest on: Engineered cancer cells
via Google News
The Latest on: Engineered cancer cells
- Merck Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon on December 20, 2018 at 5:40 am
Merck, a leading science and technology company, today announced that it has evolved its agreement with Intrexon Corporation (NASDAQ: XON) for the development of Chimeric Antigen Receptor T-cell (CAR- ... […]
- Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm on December 20, 2018 at 5:30 am
About Blastic Plasmacytoid Dendritic Cell Neoplasm Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and incurable blood cancer with a median survival ... of proprietary chimeric antigen ... […]
- Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon on December 20, 2018 at 4:42 am
for the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. The agree... […]
- What my kidney cancer is teaching me about serendipity and persistence on December 19, 2018 at 1:43 am
They are engineered in the lab to be CAR-T cells, great numbers of which are generated and infused back into the patient. They attack only those cells that carry antigens unique to the cancer. Similar ... […]
- Global engineered t cells market is expected to grow with a healthy CAGR over the forecast period from 2018-2024 on December 18, 2018 at 3:05 pm
Chimeric Antigen Receptor (CAR) The Global Engineered T Cells Market by Application • Lung Cancer • Breast Cancer • Colorectal Cancer • Melanoma • Leukemia • Others The Global Engineered T Cells Marke... […]
- CRISPR Restores Lung Cancer Sensitivity to Chemotherapy on December 18, 2018 at 7:04 am
Graham Cancer Center & Research Institute at Christiana Care ... cells were sensitive to both single and combined treatments. “In the genetically engineered knockout cell lines, we clearly observed an ... […]
- Can we teach the immune system to fight cancer? on December 13, 2018 at 3:52 pm
Precisely engineered molecules ... these very same checkpoints to make the T cells stand down, allowing the cancer cells to mutate and multiply. If unchecked, the tumors may spread, and the ... […]
- Stem cell researchers develop promising technique to generate new muscle cells in lab on December 12, 2018 at 7:12 pm
Darabi's team engineered a novel human stem cell line for skeletal muscle ... Darabi and Wang are on the faculty of The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomed... […]
- Loss of tight junction protein promotes development of precancerous cells on December 12, 2018 at 1:13 pm
Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated ... the development of precancerous, abnormal cells and polyps in the ... […]
via Bing News